DK3785733T3 - Farmaceutisk sammensætning til behandling af autisme - Google Patents
Farmaceutisk sammensætning til behandling af autisme Download PDFInfo
- Publication number
- DK3785733T3 DK3785733T3 DK20195373.4T DK20195373T DK3785733T3 DK 3785733 T3 DK3785733 T3 DK 3785733T3 DK 20195373 T DK20195373 T DK 20195373T DK 3785733 T3 DK3785733 T3 DK 3785733T3
- Authority
- DK
- Denmark
- Prior art keywords
- autism
- treatment
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762582141P | 2017-11-06 | 2017-11-06 | |
| EP17200219 | 2017-11-06 | ||
| US201862663647P | 2018-04-27 | 2018-04-27 | |
| EP18169952 | 2018-04-27 | ||
| EP18204763.9A EP3498297B1 (en) | 2017-11-06 | 2018-11-06 | Pharmaceutical composition for the treatment of autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3785733T3 true DK3785733T3 (da) | 2022-04-11 |
Family
ID=64023965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK20195373.4T DK3785733T3 (da) | 2017-11-06 | 2018-11-06 | Farmaceutisk sammensætning til behandling af autisme |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10940140B2 (da) |
| EP (3) | EP3785733B1 (da) |
| JP (2) | JP2019089755A (da) |
| KR (1) | KR102372678B1 (da) |
| CN (1) | CN109821019A (da) |
| AU (1) | AU2018260807B2 (da) |
| BR (1) | BR102018072757A2 (da) |
| CA (1) | CA3023014C (da) |
| DK (1) | DK3785733T3 (da) |
| ES (2) | ES2908863T3 (da) |
| PL (1) | PL3785733T3 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
| EP3480597A1 (en) * | 2017-11-06 | 2019-05-08 | Stalicla S.A. | Biomarker assay for use in monitoring autism |
| GB201911603D0 (en) * | 2019-08-14 | 2019-09-25 | Healx Ltd | Treatment |
| GB201912760D0 (en) * | 2019-09-05 | 2019-10-23 | Healx Ltd | Treatment |
| US20210180130A1 (en) * | 2019-12-13 | 2021-06-17 | Seawire Consultoria e Comercio LDA | Detection and treatment of autism spectrum disorders |
| EP3881842A1 (en) * | 2020-03-19 | 2021-09-22 | Stalicla S.A. | Compositions for the treatment of autism spectrum disorder |
| JP2023545589A (ja) * | 2020-10-16 | 2023-10-30 | パーパスフル アイケイイー | 組成物およびその使用 |
| EP4012414A1 (en) | 2020-12-11 | 2022-06-15 | Stalicla S.A. | Diagnosis of autism spectrum disorder phenotype 1 |
| CN113528650B (zh) * | 2021-08-03 | 2022-03-08 | 长沙艾克曼生物科技有限公司 | Tmp21基因的表达可以作为自闭症早期筛查、早期识别和症状严重程度预测的客观指标 |
| WO2023120551A1 (ja) * | 2021-12-21 | 2023-06-29 | 国立大学法人大阪大学 | 自閉スペクトラム症治療のためのオピオイドの使用 |
| WO2023198176A1 (en) * | 2022-04-15 | 2023-10-19 | Xinhua Hospital Affiliated To Shanghai Jiaotong University School Of Medicine | Prediction of the treatment response to bumetanide in subject with autism spectrum disorder |
| CN114974571B (zh) * | 2022-05-27 | 2023-03-24 | 浙江大学医学院附属儿童医院 | 多模态数据驱动的孤独症检测系统、设备及存储介质 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69926007T2 (de) | 1998-10-07 | 2005-12-29 | Medical College Of Georgia Research Institute, Inc. | Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon |
| US20050282896A1 (en) * | 2002-10-07 | 2005-12-22 | The University Of Alberta | Methods of cardioprotection using dichloroacetate in combination with an inotrope |
| US20060034941A1 (en) * | 2002-12-23 | 2006-02-16 | Global Cardiac Solutions Pty Ltd | Organ preconditioning, arrest, protection, preservation and recovery |
| DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
| EP2377530A3 (en) * | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| JP2009541354A (ja) * | 2006-06-22 | 2009-11-26 | シーブイ・セラピューティクス・インコーポレイテッド | 虚血の治療におけるａ２ａアデノシン受容体アゴニストの使用 |
| WO2008019106A1 (en) * | 2006-08-04 | 2008-02-14 | Artesian Therapeutics, Inc. | Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor |
| MX2011007759A (es) * | 2009-01-22 | 2011-10-11 | Neurotherapeutics Pharma Inc | Analogos de bumetanida, furosemida, piretanida, azosemida y torsemida, composiciones y metodos de uso. |
| EP2451456A1 (en) * | 2009-07-09 | 2012-05-16 | CBT Development Limited | Combined preparation for use as a medicament |
| SI2523661T1 (sl) * | 2010-01-15 | 2017-09-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Nkcc inhibitorji za zdravljenje avtizma |
| WO2011112961A1 (en) | 2010-03-12 | 2011-09-15 | Children's Medical Center Corporation | Methods and compositions for characterizing autism spectrum disorder based on gene expression patterns |
| US10220008B2 (en) * | 2013-08-14 | 2019-03-05 | Stc.Unm | Treatment and prevention of stroke and other neurological disorders |
| CA2925318C (en) * | 2013-09-27 | 2021-01-19 | Justin SHER | Nutraceutical composition for pde4 inhibition, enhanced dopamine metabolism and long term potentiation |
| CA3023014C (en) * | 2017-11-06 | 2023-09-26 | Stalicla Sa | Pharmaceutical composition for treatment of autism |
-
2018
- 2018-11-01 CA CA3023014A patent/CA3023014C/en active Active
- 2018-11-05 BR BR102018072757-5A patent/BR102018072757A2/pt not_active IP Right Cessation
- 2018-11-06 AU AU2018260807A patent/AU2018260807B2/en active Active
- 2018-11-06 KR KR1020180134861A patent/KR102372678B1/ko active IP Right Grant
- 2018-11-06 DK DK20195373.4T patent/DK3785733T3/da active
- 2018-11-06 EP EP20195373.4A patent/EP3785733B1/en active Active
- 2018-11-06 CN CN201811313114.6A patent/CN109821019A/zh active Pending
- 2018-11-06 JP JP2018208833A patent/JP2019089755A/ja active Pending
- 2018-11-06 EP EP21208058.4A patent/EP3984555A1/en active Pending
- 2018-11-06 US US16/182,553 patent/US10940140B2/en active Active
- 2018-11-06 EP EP18204763.9A patent/EP3498297B1/en active Active
- 2018-11-06 ES ES20195373T patent/ES2908863T3/es active Active
- 2018-11-06 ES ES18204763T patent/ES2962383T3/es active Active
- 2018-11-06 PL PL20195373T patent/PL3785733T3/pl unknown
-
2019
- 2019-10-18 JP JP2019191270A patent/JP7012054B2/ja active Active
-
2020
- 2020-12-18 US US17/126,412 patent/US11439627B2/en active Active
-
2021
- 2021-01-29 US US17/162,118 patent/US20210154177A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL3785733T3 (pl) | 2022-07-11 |
| JP2019089755A (ja) | 2019-06-13 |
| KR20190051853A (ko) | 2019-05-15 |
| JP7012054B2 (ja) | 2022-02-10 |
| KR102372678B1 (ko) | 2022-03-10 |
| EP3498297B1 (en) | 2023-06-21 |
| CN109821019A (zh) | 2019-05-31 |
| EP3785733A1 (en) | 2021-03-03 |
| ES2962383T3 (es) | 2024-03-18 |
| US10940140B2 (en) | 2021-03-09 |
| CA3023014A1 (en) | 2019-05-06 |
| BR102018072757A2 (pt) | 2019-06-04 |
| ES2908863T3 (es) | 2022-05-04 |
| EP3785733B1 (en) | 2022-01-05 |
| US20210154177A1 (en) | 2021-05-27 |
| US20190134011A1 (en) | 2019-05-09 |
| CA3023014C (en) | 2023-09-26 |
| US20210145803A1 (en) | 2021-05-20 |
| AU2018260807B2 (en) | 2020-07-09 |
| EP3984555A1 (en) | 2022-04-20 |
| US11439627B2 (en) | 2022-09-13 |
| EP3498297A1 (en) | 2019-06-19 |
| JP2020059711A (ja) | 2020-04-16 |
| EP3498297C0 (en) | 2023-06-21 |
| AU2018260807A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3785733T3 (da) | Farmaceutisk sammensætning til behandling af autisme | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3383363T3 (da) | Topiske farmaceutiske formuleringer til behandling af inflammatorisk-relaterede tilstande | |
| DK3785717T3 (da) | Fremgangsmåder til behandling af coronaviridae-infektioner | |
| DK3431105T3 (da) | Medicinsk sammensætning til behandling af cancer | |
| DK3326641T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3728271T3 (da) | Makrocykliske forbindelser til behandling af sygdomme | |
| DK3377516T3 (da) | Sammensætning til behandling af cancer | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| DK3277270T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3532029T3 (da) | Flydende farmaceutisk sammensætning | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
| DK3278801T3 (da) | Farmaceutisk sammensætning indeholdende mirabegron | |
| DK3618845T3 (da) | Peptider til behandling af diabetes | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3403674T3 (da) | Farmaceutiske sammensætninger til behandling af smerte | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| DK3373931T3 (da) | Heterocykliske forbindelser til behandling af sygdom | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom |